Today, atai Life Sciences became the third psychedelics company to list on the Nasdaq, with many spectators expecting the event to precipitate a rising tide for the broader market in the coming weeks. Cybin, meanwhile, is set to target two anxiety disorders via the development of its CYB004 molecule. Elsewhere, California’s decriminalization bill is set to be heard in the State Assembly Public…


Previous articleNuminus Wellness Graduates to Tier 1 on the TSX Venture Exchange
Next articleRed Light Holland Provides Initial FAQ in connection with Transaction with Creso Pharma